Monitoring clinical trials helps ensure clinicians remain current on evidence-based treatment options. Clinical trial data provide valuable insights into the efficacy of novel treatments, along with demonstrating the safety of those interventions. Clinicians managing patients with anxiety disorders benefit from staying informed about recruiting and soon-to-be-recruiting clinical trials. Awareness of upcoming trials allows providers to identify opportunities for patients to access novel therapies that those patients may not otherwise have access to.
Today, we have a rundown of five phase 3, currently recruiting and soon-to-be recruiting clinical trials on anxiety disorders. These trials include studies on generalized anxiety disorder and social anxiety. Their anticipated completion dates range from October 2025 through August 2027.
Currently and Soon-to-Be Recruiting Anxiety Disorder Clinical Trials
| Study Title | Phase | Recruiting | Estimated Enrollment | Start Date | Estimated Primary Completion |
|---|---|---|---|---|---|
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | 3 | Yes | 250 | 1/29/2025 | November 2026 |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | 3 | Yes | 200 | 12/11/2024 | May 2026 |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder (PALISADE-4) | 3 | Yes | 236 | 9/16/2024 | April 2026 |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder (PALISADE-3) | 3 | Yes | 236 | 3/28/2024 | October 2025 |
| Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder | 3 | Not Yet | 90 | 10/1/2025 (estimated) | 8/31/2027 |
Phase 3 Clinical Trials
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
- Sponsor: Mind Medicine, Inc.
- Goal: A Phase 3, double-blind, placebo-controlled study (part A) with an open-label extension (part B) evaluating MM120 compared to placebo in generalized anxiety disorder
- Interventions: MM120 (LSD D-Tartrate), placebo
- Primary Outcome Measures: Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at week 12.
- Timeframe: Baseline to week 12
- Study Details
- Source
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
- Sponsor: Mind Medicine, Inc.
- Goal: A Phase 3, double-blind, placebo-controlled study (part A) with an open-label extension (part B) evaluating MM120 compared to placebo in generalized anxiety disorder
- Interventions: MM120 (LSD D-Tartrate)
- Primary Outcome Measures: Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at week 12.
- Timeframe: Baseline to week 12
- Study Details
- Source
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
- Sponsor: VistaGen Therapeutics, Inc.
- Goal: This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PALISADE-4 and choose to enter the distinct open-label extension phase of the study.
- Interventions: Fasedienol nasal spray, placebo nasal spray
- Primary Outcome Measure: Subjective units of distress scale (SUDS)
- Timeframe: Seven days (visit two to visit three)
- Study Details
- Source
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
- Sponsor: VistaGen Therapeutics, Inc.
- Goal: This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PALISADE-3 and choose to enter the distinct open-label extension phase of the study.
- Interventions: Fasedienol nasal spray, placebo nasal spray
- Primary Outcome Measure: Subjective units of distress scale (SUDS)
- Timeframe: Seven days (visit two to visit three)
- Study Details
- Source
Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder
- Sponsor: Wayne State University
- Goal: This randomized, double-blind, placebo-controlled clinical trial investigates the use of FDA-approved cannabidiol (EPIDIOLEX®) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder. The study aims to evaluate whether cannabidiol-assisted CBT enhances emotion regulation via dorsomedial prefrontal cortex activation and improves anxiety symptom outcomes compared to CBT with placebo.
- Interventions: Low-dose cannabidiol, placebo matched to moderate-dose cannabidiol, moderate-dose cannabidiol, placebo match to low-dose cannabidiol
- Primary Outcome Measure: Change in dorsomedial prefrontal cortex activation when reappraising negative images
- Timeframe: Baseline to post-treatment (~week five)
- Study Details
- Source
Related Guidelines:
Cannabis for Psychological Symptoms Including Insomnia, Anxiety, and Depression
- Multinational Association of Supportive Care in Cancer, February 2025
Generalized Anxiety Disorder and Panic Disorder in Adults
- American Academy of Family Physicians, August 2022
Generalised Anxiety Disorder and Panic Disorder in Adults: Management
- National Institute for Health and Care Excellence, June 2020
Social Anxiety Disorder: Recognition, Assessment and Treatment
- National Institute for Health and Care Excellence, May 2013
Sign up for alerts and stay informed on the latest clinical trials and the guideline updates they may influence.
Copyright © 2025 Guideline Central, all rights reserved.